AICDA and non-small cell lung carcinoma: Given the emerging role of pathway-relevant signatures as basis for prognostic/predictive models linking the disease-associated gene alterations with the clinical outcome in a patient-orientated manner ([60–62] and our recent study in terms of the AID/APOBEC signature in ovarian cancer; submitted), it should be rational and achievable to apply the herein defined sphingolipid/EMT signature for assessment of NSCLC patient risk/survival.